1099:HKEXAPTOCROM Inc. Analysis
Data as of 2026-08-25 - not real-time
HK$15.77
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
At HKD 15.77, Sinopharm Group Co. Ltd. shows no decisive moving-average alignment, leaving the trend neutral. Across the trailing 30 sessions it lost 7.3%. Momentum indicators put RSI at 28.6 (oversold) with MACD reading bearish. Price has been bracketed by support at HKD 15.74 and resistance at HKD 17.88.
On valuation the read is undervalued — earnings multiple of 6.0 versus a 31.1 sector average, below the peer group. The average analyst target implies 41.5% above today's level. The 4.74% dividend yield looks covered by current payout levels.
The composite risk read is 3/10, putting it in low territory. With 30-day volatility of 21.8%, a beta of 0.14 and a maximum drawdown of 29.0%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
On valuation the read is undervalued — earnings multiple of 6.0 versus a 31.1 sector average, below the peer group. The average analyst target implies 41.5% above today's level. The 4.74% dividend yield looks covered by current payout levels.
The composite risk read is 3/10, putting it in low territory. With 30-day volatility of 21.8%, a beta of 0.14 and a maximum drawdown of 29.0%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
Top Market Events
Detailed price information for Sinopharm Group CO Ltd SHTDF from The Globe and Mail including charting and trades.Detailed price information for Sinopharm Group CO Ltd SHTDF from The Globe and Mail including charting and trades.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- RSI at 28.6 signals oversold conditions
- Trading below the 200-day average of 19.15
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- RSI at 28.6 signals oversold conditions
- P/E of 6.0 versus sector average of 31.1
- Trading below the 200-day average of 19.15
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 6.0 versus sector average of 31.1
- Analyst targets imply +41.5% versus the current price
- Revenue contracting at -0.6%
Key Metrics & Analysis
Financial Health
Revenue Growth-0.60%
Profit Margin1.24%
P/E Ratio6.0
ROE8.10%
ROA2.63%
Debt/Equity55.50
P/B Ratio0.5
Op. Cash FlowHK$16.2B
Free Cash FlowHK$-2767728128
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI28.6
SupportHK$15.74
ResistanceHK$17.88
MA 20HK$16.94
MA 50HK$16.84
MA 200HK$19.15
MACDBearish
VolumeStable
Fear & Greed Index93.13
Valuation
Fair ValueHK$33.70
Target PriceHK$22.31
Upside/Downside41.46%
GradeUndervalued
TypeValue
Dividend Yield4.74%
Risk Assessment
Beta0.14
Volatility21.78%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.